Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Patent Upheld by EPO

Premium

Alnylam Pharmaceuticals last week announced that the European Patent Office's board of appeals ruled that claims within one of the company's core patents meet the mandatory requirements under European patent law.

The patent, EP 1214945, claims methods, medicaments, and uses of siRNAs with a double-stranded structure consisting of 15 to 49 nucleotides, according to Alnylam. It is part of the so-called Kreutzer-Limmer patent family.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.